GenScript is thrilled to announce our presence at AET 2025, where we will be exhibiting at Booth #32. Join us at the Congress Center Basel, Switzerland from 10^th to 12^th June 2025.

Explore Antibody Engineering & Therapeutics Europe 2025

AET 2025 is an exceptional opportunity for us to connect with industry leaders, researchers, and innovators like yourself to explore novel approaches on antibody discovery and latest developments in bispecific antibody development. At our booth, you'll have the chance to engage with our experts, discover our cutting-edge technologies, and learn how GenScript's solutions can empower your research and projects.

We'll be showcasing our latest innovations in gene synthesis, peptide synthesis, and antibody development, as well as discussing how our tailored solutions can accelerate your scientific endeavors.

We look forward to connecting with you at this prestigious event and sharing insights into our cutting-edge products and services. Our team of experts will be on hand to address your queries and discuss the latest advancements in the antibody engineering & therapeutics space!

Join us at Booth #32 and let's explore the future of antibody engineering together!

Highlights

AET includes groundbreaking research presentations, interactive workshops, and networking opportunities with industry pioneers. From Fc engineering, bi-specific antibodies, lead generation to antibody drug discovery, we promises to ignite inspiration, foster collaboration, and chart the course for the future of science and technology.

Track Talk: Advancing CAR-T Engineering for T-ALL with CHO-Derived Recombinant scFvs and Anti-Idiotype Antibodies: Innovations and Applications by Dr Victor M. Díaz, Research Director at OneChain Immunotherapeutics

Dr Victor M. Díaz

Research Director at OneChain Immunotherapeutics

Dr. Víctor M. Díaz holds a PhD in Biochemistry and serves as Research Director at OneChain Immunotherapeutics (OCI), where he leads the development of innovative CAR-T cell therapies for hematological cancers and solid tumors. With a strong background in academic and translational research, Dr. Díaz has played a key role in advancing CAR candidates through orphan drug designations, clinical trial authorizations, and the filing of multiple patents. He currently oversees a multidisciplinary team at OCI focused on both autologous and allogeneic strategies for cancer treatment.

Our Experts at AET 2025